Product Description
Methyldopa sesquihydrate USP CEP DMF Pharmaceutical API Antihypertensive drugs made in china 41372-08-1
AI Product Description
*The following content is generated by AI and is for reference only.
Methyldopa sesquihydrate is a widely utilized pharmaceutical active ingredient (API) primarily employed in the treatment of hypertension. Manufactured under strict adherence to United States Pharmacopeia (USP), European Pharmacopoeia (CEP), and Drug Master File (DMF) standards, this compound represents a critical component in antihypertensive formulations produced globally, with significant production capacity originating from China. Chemically, Methyldopa sesquihydrate exists as the hemihydrate or sesquihydrate form of methyldopa, featuring the molecular formula C10H13NO4·1.5H2O. Its core structure consists of 3-hydroxy-α-methyl-DOPA, where the hydration state influences its physical stability, solubility profile, and bioavailability within oral dosage forms.
The primary therapeutic application of Methyldopa sesquihydrate lies in its ability to lower blood pressure by acting as a central alpha-adrenergic agonist. Upon administration, it crosses the blood-brain barrier and is decarboxylated to form alpha-methylnorepinephrine. This metabolite stimulates central alpha-2 adrenergic receptors, subsequently inhibiting sympathetic outflow from the central nervous system. This mechanism reduces peripheral vascular resistance and cardiac output, effectively managing elevated blood pressure levels. It is particularly valued for its safety profile during pregnancy, making it a first-line therapy for gestational hypertension when other agents are contraindicated or ineffective.
As a high-quality API sourced from Chinese manufacturers, Methyldopa sesquihydrate undergoes rigorous quality control testing to ensure compliance with international regulatory requirements. The product typically appears as a white to off-white crystalline powder, characterized by specific optical rotation and dissolution rates essential for consistent clinical performance. Its availability through established DMF filings facilitates streamlined drug registration processes for generic manufacturers worldwide. While generally well-tolerated, potential side effects may include sedation, dry mouth, and hepatic dysfunction, necessitating careful patient monitoring. Despite the emergence of newer antihypertensive classes, Methyldopa sesquihydrate remains a cornerstone in global cardiovascular care due to its proven efficacy, extensive clinical history, and cost-effectiveness in treating essential hypertension across diverse patient demographics.